Haemonetics Corporation
HAE
$56.66
-$1.80-3.08%
NYSE
| 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | |
|---|---|---|---|---|---|
| Net Income | 175.44M | 168.19M | 163.34M | 167.68M | 130.07M |
| Total Depreciation and Amortization | 105.91M | 107.55M | 108.51M | 108.89M | 106.42M |
| Total Amortization of Deferred Charges | 6.70M | 6.70M | 6.70M | 6.70M | 8.60M |
| Total Other Non-Cash Items | 27.39M | 30.33M | 25.17M | -867.00K | 13.24M |
| Change in Net Operating Assets | 23.41M | -23.72M | -77.18M | -100.67M | -129.07M |
| Cash from Operations | 338.84M | 289.04M | 226.54M | 181.73M | 129.25M |
| Capital Expenditure | -30.76M | -32.96M | -37.38M | -39.28M | -30.32M |
| Sale of Property, Plant, and Equipment | 3.30M | 3.12M | 3.19M | 23.25M | 21.35M |
| Cash Acquisitions | 0.00 | 0.00 | -1.76M | -150.91M | -150.91M |
| Divestitures | 43.29M | 43.29M | 43.29M | 43.29M | 1.50M |
| Other Investing Activities | -90.72M | -76.25M | -63.05M | -38.26M | -34.62M |
| Cash from Investing | -74.89M | -62.80M | -55.70M | -161.90M | -192.99M |
| Total Debt Issued | 0.00 | 0.00 | 0.00 | 950.00M | 950.00M |
| Total Debt Repaid | -6.25M | -6.25M | -4.69M | -502.69M | -564.63M |
| Issuance of Common Stock | 7.91M | 7.68M | 7.87M | 8.33M | 8.30M |
| Repurchase of Common Stock | -229.96M | -230.24M | -230.27M | -235.24M | -85.24M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -116.00K | -251.00K | -223.00K | -111.58M | -111.67M |
| Cash from Financing | -228.41M | -229.06M | -227.32M | 108.82M | 196.77M |
| Foreign Exchange rate Adjustments | 6.99M | -33.00K | 4.94M | -685.00K | -6.16M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 42.52M | -2.86M | -51.53M | 127.96M | 126.87M |